Last reviewed · How we verify
APD-209 Eye drops
APD-209 Eye drops is a Small molecule drug developed by Adenovir Pharma AB. It is currently in Phase 2 development for Treatment of dry eye disease.
APD-209 Eye drops are designed to reduce inflammation in the eye by inhibiting the action of a specific enzyme.
APD-209 Eye drops are being studied for the treatment of Viral Conjunctivitis. The therapeutic efficacy of APD-209 Eye drops is being evaluated in the treatment of Epidemic Keratoconjunctivitis (EKC), a condition that is likely related to Viral Conjunctivitis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | APD-209 Eye drops |
|---|---|
| Sponsor | Adenovir Pharma AB |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of APD-209 Eye drops involves the inhibition of a particular enzyme that plays a key role in the inflammatory process. This inhibition leads to a reduction in the production of pro-inflammatory mediators, resulting in decreased inflammation in the eye. Further research is needed to fully understand the mechanism of action of APD-209 Eye drops.
Approved indications
- Treatment of dry eye disease
Common side effects
- Eye irritation
Key clinical trials
- Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APD-209 Eye drops CI brief — competitive landscape report
- APD-209 Eye drops updates RSS · CI watch RSS
- Adenovir Pharma AB portfolio CI
Frequently asked questions about APD-209 Eye drops
What is APD-209 Eye drops?
How does APD-209 Eye drops work?
What is APD-209 Eye drops used for?
Who makes APD-209 Eye drops?
What development phase is APD-209 Eye drops in?
What are the side effects of APD-209 Eye drops?
Related
- Manufacturer: Adenovir Pharma AB — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of dry eye disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing